{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:18:55Z","timestamp":1787991535502,"version":"build-2784847793"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100005615","name":"Beth Israel Deaconess Medical Center","doi-asserted-by":"publisher","award":["GRT65864"],"award-info":[{"award-number":["GRT65864"]}],"id":[{"id":"10.13039\/100005615","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-73974-5","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:05:55Z","timestamp":1781687155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7574-1378","authenticated-orcid":false,"given":"Eleni","family":"Panagioti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4124-9948","authenticated-orcid":false,"given":"Hunter J.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L.","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leinal","family":"Sejour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Goins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotiris","family":"Sotiriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bryan Iorgulescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7811-5439","authenticated-orcid":false,"given":"Karen O.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Yaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8849-808X","authenticated-orcid":false,"given":"Ioannis S.","family":"Vlachos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean E.","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7210-5616","authenticated-orcid":false,"given":"Gordon J.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7177-2110","authenticated-orcid":false,"given":"Vijay K.","family":"Kuchroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5183-1670","authenticated-orcid":false,"given":"E.","family":"Antonio Chiocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4446-3616","authenticated-orcid":false,"given":"Charles H.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"73974_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765\u2013773 (2009).","journal-title":"N. Engl. J. Med."},{"key":"73974_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"73974_CR3","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_389322","volume":"43","author":"AB Porter","year":"2023","unstructured":"Porter, A. B., Wen, P. Y. & Polley, M. C. Molecular profiling in neuro-oncology: where we are, where we\u2019re heading, and how we ensure everyone can come along. Am. Soc. Clin. Oncol. Educ. Book 43, e389322 (2023).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"73974_CR4","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/neuonc\/noac198","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom, Q. T. et al. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. Neuro Oncol. 25, 799\u2013807 (2023).","journal-title":"Neuro Oncol."},{"key":"73974_CR5","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.3390\/cancers15143726","volume":"15","author":"M Gallus","year":"2023","unstructured":"Gallus, M., Kwok, D., Lakshmanachetty, S., Yamamichi, A. & Okada, H. Immunotherapy approaches in isocitrate-dehydrogenase-mutant low-grade glioma. Cancers 15, 3726 (2023).","journal-title":"Cancers"},{"key":"73974_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11910-023-01265-3","volume":"23","author":"R Alshiekh Nasany","year":"2023","unstructured":"Alshiekh Nasany, R. & de la Fuente, M. I. Therapies for IDH-mutant gliomas. Curr. Neurol. Neurosci. Rep. 23, 225\u2013233 (2023).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"73974_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff, I. K. et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N. Engl. J. Med 389, 589\u2013601 (2023).","journal-title":"N. Engl. J. Med"},{"key":"73974_CR8","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/S1470-2045(16)30313-8","volume":"17","author":"BG Baumert","year":"2016","unstructured":"Baumert, B. G. et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 17, 1521\u20131532 (2016).","journal-title":"Lancet Oncol."},{"key":"73974_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374\u2013403 (2023).","journal-title":"Cancer Cell"},{"key":"73974_CR10","doi-asserted-by":"publisher","first-page":"eaai8478","DOI":"10.1126\/science.aai8478","volume":"355","author":"AS Venteicher","year":"2017","unstructured":"Venteicher, A. S. et al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science 355, eaai8478 (2017).","journal-title":"Science"},{"key":"73974_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s43018-024-00865-3","volume":"6","author":"J Wu","year":"2025","unstructured":"Wu, J. et al. Evolving cell states and oncogenic drivers during the progression of IDH-mutant gliomas. Nat. Cancer 6, 145\u2013157 (2025).","journal-title":"Nat. Cancer"},{"key":"73974_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.914618","volume":"13","author":"D Yan","year":"2022","unstructured":"Yan, D., Li, W., Liu, Q. & Yang, K. Advances in immune microenvironment and immunotherapy of isocitrate dehydrogenase mutated glioma. Front Immunol. 13, 914618 (2022).","journal-title":"Front Immunol."},{"key":"73974_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42545-3","volume":"14","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma. Nat. Commun. 14, 6781 (2023).","journal-title":"Nat. Commun."},{"key":"73974_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44932-w","volume":"15","author":"S Hariharan","year":"2024","unstructured":"Hariharan, S. et al. Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas. Nat. Commun. 15, 730 (2024).","journal-title":"Nat. Commun."},{"key":"73974_CR15","doi-asserted-by":"publisher","first-page":"e154943","DOI":"10.1172\/JCI154943","volume":"132","author":"MR Waarts","year":"2022","unstructured":"Waarts, M. R., Stonestrom, A. J., Park, Y. C. & Levine, R. L. Targeting mutations in cancer. J. Clin. Invest 132, e154943 (2022).","journal-title":"J. Clin. Invest"},{"key":"73974_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.lungcan.2018.03.005","volume":"120","author":"PA Bradbury","year":"2018","unstructured":"Bradbury, P. A. et al. Canadian Cancer Trials Group (CCTG) IND211: a randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. Lung Cancer 120, 142\u2013148 (2018).","journal-title":"Lung Cancer"},{"key":"73974_CR17","doi-asserted-by":"publisher","first-page":"33946","DOI":"10.1074\/jbc.M404298200","volume":"279","author":"X Xu","year":"2004","unstructured":"Xu, X. et al. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J. Biol. Chem. 279, 33946\u201333957 (2004).","journal-title":"J. Biol. Chem."},{"key":"73974_CR18","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0969-2126(02)00904-8","volume":"10","author":"Y Yasutake","year":"2002","unstructured":"Yasutake, Y. et al. Structure of the monomeric isocitrate dehydrogenase: evidence of a protein monomerization by a domain duplication. Structure 10, 1637\u20131648 (2002).","journal-title":"Structure"},{"key":"73974_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature10866","volume":"483","author":"S Turcan","year":"2012","unstructured":"Turcan, S. et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479\u2013483 (2012).","journal-title":"Nature"},{"key":"73974_CR20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/embor.2011.43","volume":"12","author":"R Chowdhury","year":"2011","unstructured":"Chowdhury, R. et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 12, 463\u2013469 (2011).","journal-title":"EMBO Rep."},{"key":"73974_CR21","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.immuni.2025.04.017","volume":"58","author":"KW Song","year":"2025","unstructured":"Song, K. W., Lim, M. & Monje, M. Complex neural-immune interactions shape glioma immunotherapy. Immunity 58, 1140\u20131160 (2025).","journal-title":"Immunity"},{"key":"73974_CR22","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-13-0985","volume":"4","author":"I Melero","year":"2014","unstructured":"Melero, I., Rouzaut, A., Motz, G. T. & Coukos, G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov. 4, 522\u2013526 (2014).","journal-title":"Cancer Discov."},{"key":"73974_CR23","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.4049\/jimmunol.1700407","volume":"200","author":"KO Dixon","year":"2018","unstructured":"Dixon, K. O. et al. Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity. J. Immunol. 200, 3000\u20133007 (2018).","journal-title":"J. Immunol."},{"key":"73974_CR24","doi-asserted-by":"publisher","first-page":"e004711","DOI":"10.1136\/jitc-2022-004711","volume":"10","author":"EY Chiang","year":"2022","unstructured":"Chiang, E. Y. & Mellman, I. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. J. Immunother. Cancer 10, e004711 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"73974_CR25","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","volume":"55","author":"KL Banta","year":"2022","unstructured":"Banta, K. L. et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses. Immunity 55, 512\u2013526.e519 (2022).","journal-title":"Immunity"},{"key":"73974_CR26","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","volume":"627","author":"X Guan","year":"2024","unstructured":"Guan, X. et al. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T(reg) cells. Nature 627, 646\u2013655 (2024).","journal-title":"Nature"},{"key":"73974_CR27","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1038\/s43018-024-00870-6","volume":"5","author":"K Nutsch","year":"2024","unstructured":"Nutsch, K. et al. TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation. Nat. Cancer 5, 1834\u20131851 (2024).","journal-title":"Nat. Cancer"},{"key":"73974_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1039226","volume":"13","author":"H Peng","year":"2022","unstructured":"Peng, H. et al. Combination TIGIT\/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer. Front Immunol. 13, 1039226 (2022).","journal-title":"Front Immunol."},{"key":"73974_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103240","volume":"64","author":"S Zuo","year":"2021","unstructured":"Zuo, S. et al. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT). EBioMedicine 64, 103240 (2021).","journal-title":"EBioMedicine"},{"key":"73974_CR30","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","volume":"28","author":"T Todo","year":"2022","unstructured":"Todo, T. et al. Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial. Nat. Med. 28, 1630\u20131639 (2022).","journal-title":"Nat. Med."},{"key":"73974_CR31","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780\u20132788 (2015).","journal-title":"J. Clin. Oncol."},{"key":"73974_CR32","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.omtm.2020.03.028","volume":"17","author":"EA Chiocca","year":"2020","unstructured":"Chiocca, E. A., Nakashima, H., Kasai, K., Fernandez, S. A. & Oglesbee, M. Preclinical toxicology of rQNestin34.5v.2: an oncolytic herpes virus with transcriptional regulation of the ICP34.5 neurovirulence gene. Mol. Ther. Methods Clin. Dev. 17, 871\u2013893 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"73974_CR33","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.omto.2021.07.009","volume":"22","author":"JW Jackson","year":"2021","unstructured":"Jackson, J. W. et al. Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitment. Mol. Ther. Oncolytics 22, 444\u2013453 (2021).","journal-title":"Mol. Ther. Oncolytics"},{"key":"73974_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","volume":"623","author":"AL Ling","year":"2023","unstructured":"Ling, A. L. et al. Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature 623, 157\u2013166 (2023).","journal-title":"Nature"},{"key":"73974_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03612-0","volume":"7","author":"S Gao","year":"2017","unstructured":"Gao, S. et al. Overexpression of RASD1 inhibits glioma cell migration\/invasion and inactivates the AKT\/mTOR signaling pathway. Sci. Rep. 7, 3202 (2017).","journal-title":"Sci. Rep."},{"key":"73974_CR36","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez, F. J. et al. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Sci. Transl. Med. 11, 1427 (2019).","DOI":"10.1126\/scitranslmed.aaq1427"},{"key":"73974_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abh3243","volume":"7","author":"MS Alghamri","year":"2021","unstructured":"Alghamri, M. S. et al. G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy. Sci. Adv. 7, eabh3243 (2021).","journal-title":"Sci. Adv."},{"key":"73974_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08733-4","volume":"21","author":"Y Makino","year":"2021","unstructured":"Makino, Y. et al. Infrequent RAS mutation is not associated with specific histological phenotype in gliomas. BMC Cancer 21, 1025 (2021).","journal-title":"BMC Cancer"},{"key":"73974_CR39","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/ni.2667","volume":"14","author":"NA de Weerd","year":"2013","unstructured":"de Weerd, N. A. et al. Structural basis of a unique interferon-\u03b2 signaling axis mediated via the receptor IFNAR1. Nat. Immunol. 14, 901\u2013907 (2013).","journal-title":"Nat. Immunol."},{"key":"73974_CR40","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1158\/1078-0432.CCR-12-0653","volume":"18","author":"A Deisseroth","year":"2012","unstructured":"Deisseroth, A. et al. U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin. Cancer Res. 18, 3212\u20133217 (2012).","journal-title":"Clin. Cancer Res."},{"key":"73974_CR41","doi-asserted-by":"publisher","first-page":"7732","DOI":"10.18632\/oncotarget.6816","volume":"7","author":"P Cod\u00f3","year":"2016","unstructured":"Cod\u00f3, P. et al. Control of glioma cell migration and invasiveness by GDF-15. Oncotarget 7, 7732\u20137746 (2016).","journal-title":"Oncotarget"},{"key":"73974_CR42","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1002\/ijc.24639","volume":"125","author":"S Shnaper","year":"2009","unstructured":"Shnaper, S. et al. Elevated levels of MIC-1\/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int J. Cancer 125, 2624\u20132630 (2009).","journal-title":"Int J. Cancer"},{"key":"73974_CR43","first-page":"A277","volume":"9","author":"P Gokhale","year":"2021","unstructured":"Gokhale, P. et al. 256The TIGIT\/CD226\/CD155 axis and the effects of combining PD-1\/PD-L1 blockade with TIGIT-targeting antibody therapy in syngeneic murine glioblastoma models. J. Immunother. Cancer 9, A277\u2013A278 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"73974_CR44","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3171\/2014.4.JNS131198","volume":"121","author":"B Thota","year":"2014","unstructured":"Thota, B. et al. STAT-1 expression is regulated by IGFBP-3 in malignant glioma cells and is a strong predictor of poor survival in patients with glioblastoma. J. Neurosurg. 121, 374\u2013383 (2014).","journal-title":"J. Neurosurg."},{"key":"73974_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.625234","volume":"12","author":"W Ji","year":"2021","unstructured":"Ji, W. et al. Bioinformatics analysis of expression profiles and prognostic values of the signal transducer and activator of transcription family genes in glioma. Front. Genet. 12, 625234 (2021).","journal-title":"Front. Genet."},{"key":"73974_CR46","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1172\/JCI90644","volume":"127","author":"G Kohanbash","year":"2017","unstructured":"Kohanbash, G. et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J. Clin. Investig. 127, 1425\u20131437 (2017).","journal-title":"J. Clin. Investig."},{"key":"73974_CR47","doi-asserted-by":"publisher","first-page":"e20191340","DOI":"10.1084\/jem.20191340","volume":"217","author":"X Zhan","year":"2020","unstructured":"Zhan, X. et al. Glioma stem-like cells evade interferon suppression through MBD3\/NuRD complex-mediated STAT1 downregulation. J. Exp. Med. 217, e20191340 (2020).","journal-title":"J. Exp. Med."},{"key":"73974_CR48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.celrep.2017.06.036","volume":"20","author":"N Pencheva","year":"2017","unstructured":"Pencheva, N. et al. Identification of a druggable pathway controlling glioblastoma invasiveness. Cell Rep. 20, 48\u201360 (2017).","journal-title":"Cell Rep."},{"key":"73974_CR49","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11060-013-1109-3","volume":"113","author":"L Tarassishin","year":"2013","unstructured":"Tarassishin, L. & Lee, S. C. Interferon regulatory factor 3 alters glioma inflammatory and invasive properties. J. Neurooncol. 113, 185\u2013194 (2013).","journal-title":"J. Neurooncol."},{"key":"73974_CR50","doi-asserted-by":"publisher","first-page":"10576","DOI":"10.1158\/0008-5472.CAN-06-1279","volume":"66","author":"R Romieu-Mourez","year":"2006","unstructured":"Romieu-Mourez, R. et al. Distinct roles for IFN regulatory factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human macrophages. Cancer Res 66, 10576\u201310585 (2006).","journal-title":"Cancer Res"},{"key":"73974_CR51","doi-asserted-by":"publisher","first-page":"e147190","DOI":"10.1172\/jci.insight.147190","volume":"6","author":"R Huang","year":"2021","unstructured":"Huang, R., Huestis, M., Gan, E. S., Ooi, E. E. & Ohh, M. Hypoxia and viral infectious diseases. JCI Insight 6, e147190 (2021).","journal-title":"JCI Insight"},{"key":"73974_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113792","volume":"43","author":"E Farahani","year":"2024","unstructured":"Farahani, E. et al. The HIF transcription network exerts innate antiviral activity in neurons and limits brain inflammation. Cell Rep. 43, 113792 (2024).","journal-title":"Cell Rep."},{"key":"73974_CR53","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1080\/21505594.2020.1836904","volume":"11","author":"A Reyes","year":"2020","unstructured":"Reyes, A. et al. Contribution of hypoxia inducible factor-1 during viral infections. Virulence 11, 1482\u20131500 (2020).","journal-title":"Virulence"},{"key":"73974_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110470","volume":"122","author":"M Sadri","year":"2023","unstructured":"Sadri, M. et al. Hypoxia effects on oncolytic virotherapy in cancer: friend or foe? Int. Immunopharmacol. 122, 110470 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"73974_CR55","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5, 375\u2013386 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"73974_CR56","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.3390\/cancers16081600","volume":"16","author":"M Zannikou","year":"2024","unstructured":"Zannikou, M., Fish, E. N. & Platanias, L. C. Signaling by type I interferons in immune cells: disease consequences. Cancers 16, 1600 (2024).","journal-title":"Cancers"},{"key":"73974_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1023177","volume":"12","author":"B Huang","year":"2022","unstructured":"Huang, B., Lang, X. & Li, X. The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers. Front. Oncol. 12, 1023177 (2022).","journal-title":"Front. Oncol."},{"key":"73974_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108498","volume":"33","author":"GM Wiedemann","year":"2020","unstructured":"Wiedemann, G. M. et al. Divergent role for STAT5 in the adaptive responses of natural killer cells. Cell Rep. 33, 108498 (2020).","journal-title":"Cell Rep."},{"key":"73974_CR59","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nm866","volume":"9","author":"JN Blattman","year":"2003","unstructured":"Blattman, J. N. et al. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9, 540\u2013547 (2003).","journal-title":"Nat. Med."},{"key":"73974_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.631037","volume":"11","author":"MB Garcia-Fabiani","year":"2021","unstructured":"Garcia-Fabiani, M. B. et al. Genetic alterations in gliomas remodel the tumor immune microenvironment and impact immune-mediated therapies. Front. Oncol. 11, 631037 (2021).","journal-title":"Front. Oncol."},{"key":"73974_CR61","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41591-018-0263-8","volume":"25","author":"F D\u2019Angelo","year":"2019","unstructured":"D\u2019Angelo, F. et al. The molecular landscape of glioma in patients with Neurofibromatosis 1. Nat. Med. 25, 176\u2013187 (2019).","journal-title":"Nat. Med."},{"key":"73974_CR62","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/s43018-024-00772-7","volume":"5","author":"TG Chang","year":"2024","unstructured":"Chang, T. G. et al. LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features. Nat. Cancer 5, 1158\u20131175 (2024).","journal-title":"Nat. Cancer"},{"key":"73974_CR63","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1172\/JCI80445","volume":"125","author":"JM Chauvin","year":"2015","unstructured":"Chauvin, J. M. et al. TIGIT and PD-1 impair tumor antigen-specific CD8\u207a T cells in melanoma patients. J. Clin. Investig. 125, 2046\u20132058 (2015).","journal-title":"J. Clin. Investig."},{"key":"73974_CR64","doi-asserted-by":"publisher","first-page":"e1466769","DOI":"10.1080\/2162402X.2018.1466769","volume":"7","author":"AL Hung","year":"2018","unstructured":"Hung, A. L. et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology 7, e1466769 (2018).","journal-title":"Oncoimmunology"},{"key":"73974_CR65","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1001\/jamaoncol.2023.3867","volume":"9","author":"TW Kim","year":"2023","unstructured":"Kim, T. W. et al. Anti-TIGIT antibody tiragolumab alone or with atezolizumab in patients with advanced solid tumors: a phase 1a\/1b nonrandomized controlled trial. JAMA Oncol. 9, 1574\u20131582 (2023).","journal-title":"JAMA Oncol."},{"key":"73974_CR66","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","volume":"33","author":"J Niu","year":"2022","unstructured":"Niu, J. et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer(\u2606). Ann. Oncol. 33, 169\u2013180 (2022).","journal-title":"Ann. Oncol."},{"key":"73974_CR67","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1158\/1078-0432.CCR-21-2780","volume":"28","author":"NB Mettu","year":"2022","unstructured":"Mettu, N. B. et al. A Phase 1a\/b open-label, dose-escalation study of etigilimab alone or in combination with nivolumab in patients with locally advanced or metastatic solid tumors. Clin. Cancer Res. 28, 882\u2013892 (2022).","journal-title":"Clin. Cancer Res."},{"key":"73974_CR68","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho, B. C. et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 23, 781\u2013792 (2022).","journal-title":"Lancet Oncol."},{"key":"73974_CR69","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1200\/JCO.23.01363","volume":"42","author":"CM Rudin","year":"2024","unstructured":"Rudin, C. M. et al. SKYSCRAPER-02: tiragolumab in combination with atezolizumab plus chemotherapy in untreated extensive-stage small-cell lung cancer. J. Clin. Oncol. 42, 324\u2013335 (2024).","journal-title":"J. Clin. Oncol."},{"key":"73974_CR70","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41591-024-03411-x","volume":"31","author":"R Dummer","year":"2025","unstructured":"Dummer, R. et al. Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1\/2 trial. Nat. Med. 31, 144\u2013151 (2025).","journal-title":"Nat. Med."},{"key":"73974_CR71","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.3390\/v14112327","volume":"14","author":"J Ding","year":"2022","unstructured":"Ding, J. et al. Pre-existing HSV-1 immunity enhances anticancer efficacy of a novel immune-stimulating oncolytic virus. Viruses 14, 2327 (2022).","journal-title":"Viruses"},{"key":"73974_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2023.01.002","volume":"70","author":"C Groeneveldt","year":"2023","unstructured":"Groeneveldt, C., van den Ende, J. & van Montfoort, N. Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy? Cytokine Growth Factor Rev. 70, 1\u201312 (2023).","journal-title":"Cytokine Growth Factor Rev."},{"key":"73974_CR73","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.cell.2025.12.055","volume":"189","author":"M Meylan","year":"2026","unstructured":"Meylan, M. et al. Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial. Cell 189, 1287\u20131304.e18 (2026).","journal-title":"Cell"},{"key":"73974_CR74","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/neuonc\/nor195","volume":"14","author":"H Wakimoto","year":"2012","unstructured":"Wakimoto, H. et al. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol. 14, 132\u2013144 (2012).","journal-title":"Neuro Oncol."},{"key":"73974_CR75","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/BF00686188","volume":"36","author":"PJ Houghton","year":"1995","unstructured":"Houghton, P. J. et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharm. 36, 393\u2013403 (1995).","journal-title":"Cancer Chemother. Pharm."},{"key":"73974_CR76","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1158\/1538-7445.AM2023-2990","volume":"83","author":"B Iorgulescu","year":"2023","unstructured":"Iorgulescu, B. et al. Antigen presentation deficiency and mesenchymal differentiation underlie resistance to immunotherapy in the murine syngeneic CT2A tumor model. Cancer Res. 83, 2990\u20132990 (2023).","journal-title":"Cancer Res."},{"key":"73974_CR77","first-page":"52443","volume":"22","author":"AA Calinescu","year":"2015","unstructured":"Calinescu, A. A. et al. Transposon mediated integration of plasmid DNA into the subventricular zone of neonatal mice to generate novel models of glioblastoma. J. Vis. Exp. 22, 52443 (2015).","journal-title":"J. Vis. Exp."},{"key":"73974_CR78","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1158\/0008-5472.CAN-04-3227","volume":"65","author":"H Kambara","year":"2005","unstructured":"Kambara, H., Okano, H., Chiocca, E. A. & Saeki, Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res. 65, 2832\u20132839 (2005).","journal-title":"Cancer Res."},{"key":"73974_CR79","unstructured":"National Research Council Committee for the Update of the Guide for the, C. & Use of Laboratory, A. in Guide for the Care and Use of Laboratory Animals (National Academies Press, 2011)."},{"key":"73974_CR80","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1089\/mab.2021.0068","volume":"41","author":"MT Bu","year":"2022","unstructured":"Bu, M. T., Yuan, L., Klee, A. N. & Freeman, G. J. A comparison of murine PD-1 and PD-L1 monoclonal antibodies. Monoclon. Antib. Immunodiagn. Immunother. 41, 202\u2013209 (2022).","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"73974_CR81","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/2326-6066.CIR-15-0151","volume":"4","author":"DA Reardon","year":"2016","unstructured":"Reardon, D. A. et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol. Res 4, 124\u2013135 (2016).","journal-title":"Cancer Immunol. Res"},{"key":"73974_CR82","doi-asserted-by":"crossref","unstructured":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061\u20131068 (2008).","DOI":"10.1038\/nature07385"},{"key":"73974_CR83","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41588-021-00791-5","volume":"53","author":"AP Heath","year":"2021","unstructured":"Heath, A. P. et al. The NCI genomic data commons. Nat. Genet 53, 257\u2013262 (2021).","journal-title":"Nat. Genet"},{"key":"73974_CR84","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico, A. et al. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 44, e71 (2016).","journal-title":"Nucleic Acids Res."},{"key":"73974_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"73974_CR86","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).","journal-title":"Innovation"},{"key":"73974_CR87","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"73974_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 14, 7 (2013).","journal-title":"BMC Bioinforma."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73974-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73974-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73974-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:04:04Z","timestamp":1785755044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73974-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73974"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73974-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.A.C. is named inventor on patents related to rQNestin34.5\u2009v.2. E.A.C. is an advisor to Bionaut Labs, Seneca Therapeutics, ReIgnite and Calidi. He has equity options in Bionaut Laboratories, Seneca Therapeutics, ReIgnite, Ternalys Therapeutics. He is co-founder and on Board of Directors of Ternalys Therapeutics. He has received research support from NIH, US Department of Defense, American Brain Tumor Association, National Brain Tumor Society, Alliance for Cancer Gene Therapy, Neurosurgical Research Education Foundation, Advantagene, NewLink Genetics, and Amgen. The Patents related to oHSV and CAN-3110 are under the possession of Brigham and Women\u2019s Hospital (BWH) with E.A.C. named as inventor. These patents have been licensed to Candel Therapeutics, Inc. Present and future milestone license fees and future royalty fees are distributed to BWH from Candel. I.S.V. reports grants from NCI, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, Harvard Stem Cell Institute and consulting for Mosaic, AlphaSights, Chronicle Medical Software Inc., and Guidepoint Global outside of the submitted work. G.J.F. has patents\/pending royalties on the PD-L1\/PD-1 pathway from Roche, Merck MSD, AstraZeneca, Bristol-Myers-Squibb, Merck KGA, Boehringer-Ingelheim, Dako, Leica, Mayo Clinic, Eli Lilly, Coherus BioSciences, and Novartis. G.J.F. has served on advisory boards for iTeos, NextPoint, IgM, GV20, IOME, Bioentre, Santa Ana Bio, Simcere of America, and Geode. G.J.F. has equity in Nextpoint, iTeos, IgM, Invaria, GV20, Bioentre, and Geode. V.K.K. has an ownership interest and is a member of the SAB for Tizona and Trishula Therapeutics. V.K.K. is an inventor on patents related to Th17 cells and immunometabolism. V.K.K. has an ownership interest in Tizona Therapeutics, Trishula, Celsius Therapeutics, Bicara Therapeutics, Larkspur Therapeutics and Werewolf Therapeutics. V.K.K. has financial interests in Biocon Biologic, Compass, Elpiscience Biopharmaceutical, Equilium, PerkinElmer and Syngene. V.K.K. is a member of SABs for Cell Signaling Technology, Elpiscience Biopharmaceutical, Larkspur, Tizona Therapeutics, Tr1X and Werewolf. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7661"}}